Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Axsome Therapeutics Announces Further Progress in AXS-05 Depression Clinical Program
11:00am, Monday, 10'th Aug 2020
Enrollment complete in the COMET Phase 3 long-term safety trial of AXS-05 in MDD; NDA filing on track for 4Q 2020Results from three Phase 2 open-label efficacy trials of AXS-05 in TRD, antidepressant
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
12:00am, Sunday, 09'th Aug 2020
Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-12 for the Treatment of Narcolepsy
11:00am, Wednesday, 05'th Aug 2020
Designation offers potential for expedited development and review FDA Orphan Drug Designation previously granted to Axsome for AXS-12 in narcolepsyThird FDA Breakthrough Therapy designation received
Axsome Therapeutics: Big Unfolding Catalyst (NASDAQ:AXSM)
09:19am, Wednesday, 05'th Aug 2020
Axsome continues to deliver a flurry of positive catalysts for various pipeline molecules. Despite subpar data for the treatment-resistant depression, AXS-05 generated extremely robust results for oth
BidaskClub Downgrades Axsome Therapeutics (NASDAQ:AXSM) to Sell
05:16am, Monday, 03'rd Aug 2020
Axsome Therapeutics (NASDAQ:AXSM) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Saturday, BidAskClub reports. Several othe
Harmony Biosciences Starts U.S. IPO Effort
12:23pm, Friday, 31'st Jul 2020
Harmony Biosciences has filed to raise $100 million in an IPO, although the final figure will likely differ.
Axsome Therapeutics to Report Second Quarter 2020 Financial Results on August 10, 2020
11:00am, Thursday, 30'th Jul 2020
Axsome to host conference call and webcast on Monday, August 10, 2020 at 8:00 AM Eastern TimeNEW YORK, July 30, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical c
The Secondary Impact Of COVID-19 Pandemic Leads To Bigger Market Potential For Axsome Therapeutics
01:43pm, Monday, 27'th Jul 2020
Since the pandemic started, the market has overly-emphasized on COVID-19 vaccines but ignored its secondary impact: mental health.
These Stocks Would Have Doubled Your Money Last Year
11:10am, Saturday, 25'th Jul 2020
Axsome Therapeutics and EverQuote had two of the biggest stock gains in 2019. Are they still buys today?
Were Hedge Funds Right About Axsome Therapeutics, Inc. (AXSM)?
04:21pm, Thursday, 16'th Jul 2020
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail invest
Steven Cohen Homes in on Otonomy by Expanding Stake
05:15pm, Wednesday, 15'th Jul 2020
Guru ups bet in biotech focused on ear-related disorders Continue reading...
Axsome Focuses on Filling NDAs for Two CNS Candidates in 2020
04:05pm, Wednesday, 15'th Jul 2020
Axsome's (AXSM) CNS pipeline candidates are advancing well. NDAs for AXS-05 to address MDD and AXS-07 as an acute treatment of migraine will be filed in Q4. Lack of a marketed product is a concern.
Axsome's NDA for Depressive Disorder Drug on Track in Q420
04:16pm, Tuesday, 14'th Jul 2020
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA officials for AXS-05 to treat major depressive disorder. The company is on course to file the NDA in Q4.
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-05 for the Treatment of Major Depressive Disorder
11:00am, Monday, 13'th Jul 2020
NDA submission on track for 4Q 2020 NEW YORK, July 13, 2020 -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the.
